Federation Des Caisses Desjardins Du Quebec Avadel Pharmaceuticals PLC Transaction History

Federation Des Caisses Desjardins Du Quebec

$18.9 Billion
Q3 2024

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 Aug 30, 2024	SELL	$6.61 - $10.07 $132 - $201	-20 Closed	0 $0
Q1 2020 Aug 30, 2024	BUY	$4.06 - $10.64 $81 - $212	20 New	20 $159,000
Q3 2019 Aug 30, 2024	SELL	$1.92 - $4.47 $55,566 - $129,366	-28,941 Closed	0 $0
Q4 2018 Aug 30, 2024	BUY	$1.74 - $4.66 $50,357 - $134,865	28,941 New	28,941 $74.8 Million
Q2 2017 Aug 30, 2024	BUY	N/A	4,994 Added 20.85%	28,941 $319 Million
Q1 2017 Aug 30, 2024	BUY	N/A	23,947	23,947 $232 Million

Others Institutions Holding AVDL

# of Institutions

Shares Held

1.07M

Call Options Held

Put Options Held

View Full List

About AVADEL PHARMACEUTICALS PLC

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $650M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

More about AVDL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federation Des Caisses Desjardins Du Quebec, based on Form 13F filings with the SEC.

News

Stay updated on Federation Des Caisses Desjardins Du Quebec with notifications on news.

Account